(3S)-tert-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate | 942143-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3S)-tert-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3S)-3-[1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl]piperidine-1-carboxylate
• CAS: 942143-24-0
• 化学式: C₂₂H₃₃FN₂O₄
• 分子量: 408.513
• InChiKey: GMGXQICCUBDXBG-DUSLRRAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (3S)-tert-butyl 3-(4-amino-1-(3-fluorophenyl)butyl)piperidine-1-carboxylate trifluoroacetate 、 氯甲酸甲酯 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以38%的产率得到(3S)-tert-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2007/70201

  摘要：

  公开号：

文献信息

• Phosphodiesterase 4 inhibitors
  申请人：Dunn F. Robert

  公开号：US20070254913A1

  公开（公告）日：2007-11-01

  Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.

  选择性PDE4抑制是通过芳基和杂环基吡唑化合物实现的。与罗利普兰（rolipram）等化合物相比，这些化合物表现出更好的PDE4抑制作用，并且在抑制其他类PDE时表现出选择性。
• PHOSPHODIESTERASE 4 INHIBITORS
  申请人：HOPPER Allen

  公开号：US20080207660A1

  公开（公告）日：2008-08-28

  Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.

  选择性PDE4抑制是由芳基和杂环基吡唑化合物实现的。这些化合物与类似于罗利普兰的化合物相比，表现出更好的PDE4抑制作用，并且在抑制其他类别的PDE方面表现出选择性。
• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
  申请人：Baldwin John J.

  公开号：US08487108B2

  公开（公告）日：2013-07-16

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包含所述天冬氨酸蛋白酶抑制剂的制药组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的受体的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• ASPARTIC PROTEASE INHIBITORS
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP1966139B1

  公开（公告）日：2011-12-21